Skip to main content
Journal cover image

Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.

Publication ,  Journal Article
Reiher, FK; Volpert, OV; Jimenez, B; Crawford, SE; Dinney, CP; Henkin, J; Haviv, F; Bouck, NP; Campbell, SC
Published in: Int J Cancer
April 10, 2002

Many normal human cells produce thrombospondin-1 (TSP-1), a potent antiangiogenic protein that promotes vascular quiescence. In various organ systems, including the brain, breast and bladder and in fibroblasts, TSP-1 secretion is reduced during tumorigenesis, thereby allowing induction of the vigorous neovascularization required for tumor growth and metastasis. Full-length and short TSP-1-derived peptides inhibit angiogenesis by inducing endothelial cell apoptosis and thus disrupting the vasculature of the growing tumor. CD36 expressed on the surface of endothelial cells functions as the primary antiangiogenic receptor for TSP-1. A D-isoleucyl enantiomer of a TSP-1 heptapeptide specifically inhibits the proliferation and migration of capillary endothelial cells. DI-TSP, an approximately 1 kDa capped version of this peptide, is also antiangiogenic in vitro, with a specific activity approaching that of the 450 kDa parental molecule. Here, we show that DI-TSP delivered systemically dose-dependently inhibits the growth of murine melanoma metastases in syngeneic animals and that its more soluble isomer, DI-TSPa, similarly blocks the progression of primary human bladder tumors in an orthotopic model in immune-deficient mice. Like intact TSP-1, these peptide mimetics had no effect on cancer cells growing in vitro but markedly suppressed the growth of endothelial cells by inducing receptor-dependent apoptosis. Antibodies raised against CD36 blocked the ability of peptides to induce apoptosis in endothelial cells but had no effect on tumor necrosis factor-alpha-induced apoptosis. In vivo, the peptide mimetics were associated with a significantly reduced microvessel density and increased apoptotic indices in both the endothelial and tumor cell compartments. Such short peptides targeted to a specific antiangiogenic receptor, potent and easy to synthesize, show great promise as lead compounds in clinical antiangiogenic strategies.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Int J Cancer

DOI

ISSN

0020-7136

Publication Date

April 10, 2002

Volume

98

Issue

5

Start / End Page

682 / 689

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Thrombospondin 1
  • Proliferating Cell Nuclear Antigen
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Peptide Fragments
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Molecular Mimicry
  • Mice, Nude
  • Mice, Inbred C57BL
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Reiher, F. K., Volpert, O. V., Jimenez, B., Crawford, S. E., Dinney, C. P., Henkin, J., … Campbell, S. C. (2002). Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer, 98(5), 682–689. https://doi.org/10.1002/ijc.10247
Reiher, Frank K., Olga V. Volpert, Benilde Jimenez, Susan E. Crawford, Colin P. Dinney, Jack Henkin, Fortuna Haviv, Noel P. Bouck, and Steven C. Campbell. “Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.Int J Cancer 98, no. 5 (April 10, 2002): 682–89. https://doi.org/10.1002/ijc.10247.
Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, et al. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer. 2002 Apr 10;98(5):682–9.
Reiher, Frank K., et al. “Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics.Int J Cancer, vol. 98, no. 5, Apr. 2002, pp. 682–89. Pubmed, doi:10.1002/ijc.10247.
Reiher FK, Volpert OV, Jimenez B, Crawford SE, Dinney CP, Henkin J, Haviv F, Bouck NP, Campbell SC. Inhibition of tumor growth by systemic treatment with thrombospondin-1 peptide mimetics. Int J Cancer. 2002 Apr 10;98(5):682–689.
Journal cover image

Published In

Int J Cancer

DOI

ISSN

0020-7136

Publication Date

April 10, 2002

Volume

98

Issue

5

Start / End Page

682 / 689

Location

United States

Related Subject Headings

  • Urinary Bladder Neoplasms
  • Thrombospondin 1
  • Proliferating Cell Nuclear Antigen
  • Platelet Endothelial Cell Adhesion Molecule-1
  • Peptide Fragments
  • Oncology & Carcinogenesis
  • Neovascularization, Pathologic
  • Molecular Mimicry
  • Mice, Nude
  • Mice, Inbred C57BL